Free Trial
NASDAQ:NRSN

NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

NeuroSense Therapeutics logo
$1.23
-0.04 (-3.15%)
(As of 11/4/2024 ET)

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

Key Stats

Today's Range
$1.14
$1.34
50-Day Range
$0.71
$1.35
52-Week Range
$0.43
$2.33
Volume
388,594 shs
Average Volume
267,170 shs
Market Capitalization
$16.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

NeuroSense Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
23rd Percentile Overall Score

NRSN MarketRank™: 

NeuroSense Therapeutics scored higher than 23% of companies evaluated by MarketBeat, and ranked 879th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroSense Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroSense Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about NeuroSense Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.62% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently decreased by 23.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NeuroSense Therapeutics does not currently pay a dividend.

  • Dividend Growth

    NeuroSense Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.62% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently decreased by 23.32%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NeuroSense Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for NeuroSense Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    4 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.04% of the stock of NeuroSense Therapeutics is held by institutions.

  • Read more about NeuroSense Therapeutics' insider trading history.
Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRSN Stock News Headlines

NeuroSense Completes Key ALS Trial Phase
Neurosense Therapeutics Secures $30 Million Equity Deal
The Final Frontier
And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.
NeuroSense Therapeutics Advances ALS Drug Development Plans
NeuroSense’s PrimeC shows microRNA improvement in ALS
NeuroSense’s PrimeC Shows Potential in ALS Treatment
See More Headlines

NRSN Stock Analysis - Frequently Asked Questions

NeuroSense Therapeutics' stock was trading at $0.7850 at the beginning of the year. Since then, NRSN shares have increased by 56.7% and is now trading at $1.23.
View the best growth stocks for 2024 here
.

NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE).

Company Calendar

Today
11/04/2024
Next Earnings (Estimated)
11/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRSN
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Net Income
$-11,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.14) per share

Miscellaneous

Free Float
9,922,000
Market Cap
$16.81 million
Optionable
Not Optionable
Beta
1.58
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:NRSN) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners